CN101268084A - 天冬氨酸特异性半胱氨酸蛋白酶抑制剂前体药物 - Google Patents

天冬氨酸特异性半胱氨酸蛋白酶抑制剂前体药物 Download PDF

Info

Publication number
CN101268084A
CN101268084A CNA2006800345091A CN200680034509A CN101268084A CN 101268084 A CN101268084 A CN 101268084A CN A2006800345091 A CNA2006800345091 A CN A2006800345091A CN 200680034509 A CN200680034509 A CN 200680034509A CN 101268084 A CN101268084 A CN 101268084A
Authority
CN
China
Prior art keywords
alkyl
group
membered
ring
disease
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CNA2006800345091A
Other languages
English (en)
Chinese (zh)
Inventor
S·达兰特
J-D·凯瑞尔
J·斯杜德雷
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Vertex Pharmaceuticals Inc
Original Assignee
Vertex Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vertex Pharmaceuticals Inc filed Critical Vertex Pharmaceuticals Inc
Publication of CN101268084A publication Critical patent/CN101268084A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/429—Thiazoles condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurology (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • Virology (AREA)
  • Diabetes (AREA)
  • Neurosurgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Communicable Diseases (AREA)
  • Hematology (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Molecular Biology (AREA)
  • Endocrinology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Psychology (AREA)
  • Cardiology (AREA)
  • Biotechnology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Hospice & Palliative Care (AREA)
CNA2006800345091A 2005-07-28 2006-07-20 天冬氨酸特异性半胱氨酸蛋白酶抑制剂前体药物 Pending CN101268084A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US70337505P 2005-07-28 2005-07-28
US60/703,375 2005-07-28

Publications (1)

Publication Number Publication Date
CN101268084A true CN101268084A (zh) 2008-09-17

Family

ID=37709070

Family Applications (1)

Application Number Title Priority Date Filing Date
CNA2006800345091A Pending CN101268084A (zh) 2005-07-28 2006-07-20 天冬氨酸特异性半胱氨酸蛋白酶抑制剂前体药物

Country Status (14)

Country Link
US (2) US7879891B2 (https=)
EP (1) EP1910379B1 (https=)
JP (1) JP2009502922A (https=)
KR (1) KR20080038369A (https=)
CN (1) CN101268084A (https=)
AT (1) ATE529430T1 (https=)
AU (1) AU2006276096A1 (https=)
CA (1) CA2616337A1 (https=)
IL (1) IL188997A0 (https=)
NO (1) NO20081050L (https=)
NZ (1) NZ566022A (https=)
RU (1) RU2427582C2 (https=)
WO (1) WO2007015931A2 (https=)
ZA (1) ZA200801172B (https=)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101979403A (zh) * 2010-09-13 2011-02-23 沈陵陵 新型半胱氨酸天冬氨酸广谱蛋白酶抑制剂及其制备方法和用途
CN102741259A (zh) * 2009-07-31 2012-10-17 全球结核病药物研发联盟 硝基咪唑并噁嗪和硝基咪唑并噁唑的类似物及其用途
CN107793434A (zh) * 2016-09-07 2018-03-13 帝斯曼知识产权资产管理有限公司 用于制备经取代的咪唑并噻唑酮的方法

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20050159A1 (es) 2003-05-27 2005-04-19 Vertex Pharma Derivados de acido 3-[2-(3-amino-2-oxo-2h-piridin-1-il)-acetilamino]-4-oxo-pentanoico como inhibidores de caspasa
WO2005115362A1 (en) * 2004-05-15 2005-12-08 Vertex Pharmaceuticals Incorporated Treating seizures using ice inhibitors
ATE543803T1 (de) * 2004-11-24 2012-02-15 Vertex Pharma 3-ä2-(3-azylamino-2-oxo-2h-pyridin-1- yl)acetylaminoü-4-oxopentansäurederivate und deren verwendung als caspase-inhibitoren
MX2008005814A (es) 2005-11-03 2008-10-15 Vertex Pharma Aminopirimidinas utiles como inhibidores de cinasa.
KR20090099886A (ko) * 2008-03-18 2009-09-23 주식회사 엘지생명과학 캐스파제 저해제의 프로드럭
WO2010017408A1 (en) 2008-08-06 2010-02-11 The Buck Institute For Age Research Caspase inhibitors and uses thereof
RU2542103C2 (ru) * 2009-05-22 2015-02-20 Эббви Инк. Модуляторы рецепторов 5-нт и способы их применения
CA2769359C (en) * 2009-07-31 2017-03-07 Global Alliance For Tb Drug Development Nitroimidazooxazines and their uses in anti-tubercular therapy
WO2011146089A1 (en) * 2010-05-21 2011-11-24 Abbott Laboratories Modulators of 5-ht receptors and methods of use thereof
US9956260B1 (en) 2011-07-22 2018-05-01 The J. David Gladstone Institutes Treatment of HIV-1 infection and AIDS
JP2022529973A (ja) * 2019-04-19 2022-06-27 エルジー・ケム・リミテッド カスパーゼ阻害剤のプロドラッグ
KR102442103B1 (ko) 2019-04-30 2022-09-08 주식회사 엘지화학 캐스파제 저해제의 프로드럭
KR102366226B1 (ko) 2019-05-31 2022-02-22 주식회사 엘지화학 캐스파제 저해제 프로드럭을 함유하는 주사용 조성물 및 이의 제조 방법
JP7362184B2 (ja) 2019-05-31 2023-10-17 エルジー・ケム・リミテッド カスパーゼ阻害剤プロドラッグの注射用組成物
KR102670554B1 (ko) 2022-01-04 2024-05-30 주식회사 이노보테라퓨틱스 캐스파제 저해제로서의 신규한 이소인돌리논 유도체 화합물
WO2025221068A1 (ko) * 2024-04-19 2025-10-23 (주)노보메디슨 심장질환의 예방 또는 치료를 위한 캐스파제 저해제

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5874424A (en) 1995-12-20 1999-02-23 Vertex Pharmaceuticals Incorporated Inhibitors of interleukin-1β converting enzyme
SU1441748A1 (ru) * 1987-03-04 1995-09-10 Пермский государственный университет 3-(4-бромфенил)-3а,4,6,6а-тетрагидрофуро[3,4-d]изоксазол-4-он, проявляющий противовоспалительную активность
SU1586154A1 (ru) * 1988-09-15 2006-12-20 Краснодарский политехнический институт 3-(2,4-Дихлорфенил)-4-оксо-3a,4,6,6a-тетрагидрофуро-[3,4-d]изоксазол, проявляющий антигельминтную и анальгетическую активность
US5847135A (en) 1994-06-17 1998-12-08 Vertex Pharmaceuticals, Incorporated Inhibitors of interleukin-1β converting enzyme
US5716929A (en) 1994-06-17 1998-02-10 Vertex Pharmaceuticals, Inc. Inhibitors of interleukin-1β converting enzyme
US5756466A (en) 1994-06-17 1998-05-26 Vertex Pharmaceuticals, Inc. Inhibitors of interleukin-1β converting enzyme
ES2208690T3 (es) * 1994-08-30 2004-06-16 Sankyo Company Limited Isoxazol.
US5672584A (en) * 1995-04-25 1997-09-30 The University Of Kansas Cyclic prodrugs of peptides and peptide nucleic acids having improved metabolic stability and cell membrane permeability
US5843904A (en) 1995-12-20 1998-12-01 Vertex Pharmaceuticals, Inc. Inhibitors of interleukin-1βconverting enzyme
NZ330451A (https=) 1996-09-12 2000-01-28 Idun Pharmaceuticals Inc
DE69718012T2 (de) 1996-09-12 2003-09-25 Idun Pharmaceuticals, Inc. C-terminale modifizierte (n-substituierte)-2-indolyl dipeptide als inhibitoren von der ice/ced-3 cysteinprotease familie
AU738048B2 (en) 1996-09-12 2001-09-06 Idun Pharmaceuticals, Inc. Inhibition of apoptosis using interleukin-1beta-converting enzyme (ICE)/CED-3 family inhibitors
US5968927A (en) 1996-09-20 1999-10-19 Idun Pharmaceuticals, Inc. Tricyclic compounds for the inhibition of the ICE/ced-3 protease family of enzymes
AU738341B2 (en) 1996-10-11 2001-09-13 Abbott Gmbh & Co. Kg Asparate ester inhibitors of interleukin-1beta converting enzyme
US5919790A (en) 1996-10-11 1999-07-06 Warner-Lambert Company Hydroxamate inhibitors of interleukin-1β converting enzyme
US6184244B1 (en) 1996-12-16 2001-02-06 Idun Pharmaceuticals, Inc. C-terminal modified (N-substituted)-2-indolyl dipeptides as inhibitors of the ICE/ced-3 family of cysteine proteases
US6184210B1 (en) 1997-10-10 2001-02-06 Cytovia, Inc. Dipeptide apoptosis inhibitors and the use thereof
PT1049703E (pt) 1998-01-20 2003-06-30 Warner Lambert Co Aldeido do acido n-¬2-(5-benziloxicarbonilamino-6-oxo-2-(4-fluorofenil)-1,6-di-hidro-1-pirimidinil)acetoxil|-l-aspartico como inibidor da enzima de conversao da interleucina-1beta in vivo
WO1999046248A1 (en) * 1998-03-09 1999-09-16 Vertex Pharmaceuticals Incorporated 1,2-diazepane derivatives as interleukin-1beta converting enzyme inhibitors
TWI243828B (en) 1998-03-19 2005-11-21 Vertex Pharma Inhibitors of caspases
US6197750B1 (en) * 1998-07-02 2001-03-06 Idun Pharmaceuticals, Inc. C-terminal modified oxamyl dipeptides as inhibitors of the ICE/ced-3 family of cysteine proteases
US6242422B1 (en) 1998-10-22 2001-06-05 Idun Pharmacueticals, Inc. (Substituted)Acyl dipeptidyl inhibitors of the ice/ced-3 family of cysteine proteases
ATE344249T1 (de) 1999-07-19 2006-11-15 Merck Frosst Canada Ltd Pyrazinone, diese verbindungen enthaltende zusammenstellungen
DE60010675T2 (de) 1999-08-06 2005-06-16 Vertex Pharmaceuticals Inc., Cambridge Caspase inhibitoren und deren verwendung
AR026748A1 (es) 1999-12-08 2003-02-26 Vertex Pharma Un compuesto inhibidor de caspasas, una composicion farmaceutica que lo comprende, un metodo para la sintesis del mismo y un compuesto intermediario paradicha sintesis
AU2001249619B2 (en) * 2000-03-29 2006-08-17 Vertex Pharmaceuticals Incorporated Carbamate caspase inhibitors and uses thereof
EP1278737B1 (en) 2000-04-24 2010-06-30 Vertex Pharmaceuticals Incorporated Process and intermediates for making substituted aspartic acid acetals
PE20011350A1 (es) * 2000-05-19 2002-01-15 Vertex Pharma PROFARMACO DE UN INHIBIDOR DE ENZIMA CONVERTIDORA DE INTERLEUCINA-1ß (ICE)
KR20020025959A (ko) 2000-05-23 2002-04-04 버텍스 파마슈티칼스 인코포레이티드 카스파제 억제제 및 이의 용도
WO2001094351A1 (en) 2000-06-07 2001-12-13 Vertex Pharmaceuticals Incorporated Caspase inhibitors and uses thereof
CA2418720A1 (en) 2000-09-13 2002-03-21 Vertex Pharmaceuticals Incorporated Caspase inhibitors and uses thereof
DE60127860T2 (de) 2000-11-21 2008-01-17 Vertex Pharmaceuticals Inc., Cambridge Imidazol- und benzimidazol- caspase inhibitoren und deren verwendung
US20030096737A1 (en) 2001-04-19 2003-05-22 Anita Diu-Hercend Caspase inhibitors and uses thereof
WO2002094263A2 (en) 2001-05-23 2002-11-28 Vertex Pharmaceuticals Incorporated Caspase inhibitors and uses thereof
PL374598A1 (en) * 2002-06-28 2005-10-31 Vertex Pharmaceuticals Incorporated Caspase inhibitors and uses thereof
PE20050159A1 (es) * 2003-05-27 2005-04-19 Vertex Pharma Derivados de acido 3-[2-(3-amino-2-oxo-2h-piridin-1-il)-acetilamino]-4-oxo-pentanoico como inhibidores de caspasa

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102741259A (zh) * 2009-07-31 2012-10-17 全球结核病药物研发联盟 硝基咪唑并噁嗪和硝基咪唑并噁唑的类似物及其用途
CN102741259B (zh) * 2009-07-31 2016-04-13 全球结核病药物研发联盟 硝基咪唑并噁嗪和硝基咪唑并噁唑的类似物及其用途
CN101979403A (zh) * 2010-09-13 2011-02-23 沈陵陵 新型半胱氨酸天冬氨酸广谱蛋白酶抑制剂及其制备方法和用途
CN107793434A (zh) * 2016-09-07 2018-03-13 帝斯曼知识产权资产管理有限公司 用于制备经取代的咪唑并噻唑酮的方法
CN107793434B (zh) * 2016-09-07 2022-05-24 帝斯曼知识产权资产管理有限公司 用于制备经取代的咪唑并噻唑酮的方法

Also Published As

Publication number Publication date
NZ566022A (en) 2011-04-29
RU2008107576A (ru) 2009-09-10
NO20081050L (no) 2008-04-28
CA2616337A1 (en) 2007-02-08
US7879891B2 (en) 2011-02-01
EP1910379A2 (en) 2008-04-16
WO2007015931A2 (en) 2007-02-08
KR20080038369A (ko) 2008-05-06
IL188997A0 (en) 2008-08-07
RU2427582C2 (ru) 2011-08-27
WO2007015931A3 (en) 2007-06-07
ZA200801172B (en) 2009-04-29
AU2006276096A1 (en) 2007-02-08
US20110137037A1 (en) 2011-06-09
US20070155718A1 (en) 2007-07-05
JP2009502922A (ja) 2009-01-29
EP1910379B1 (en) 2011-10-19
US8168798B2 (en) 2012-05-01
ATE529430T1 (de) 2011-11-15

Similar Documents

Publication Publication Date Title
US8168798B2 (en) Caspase inhibitor prodrugs
CN113286794B (zh) Kras突变蛋白抑制剂
KR102680164B1 (ko) Rock 억제제로서의 페닐아세트아미드
CN112566916B (zh) 作为pad4抑制剂的经取代的噻吩并吡咯
KR100814599B1 (ko) 신경퇴행성 장애 치료용 이미다졸 화합물
CN112805067B (zh) Pad酶的吲哚及氮杂吲哚抑制剂
JP2007508363A (ja) Ｃｒｔｈ２アンタゴニスト活性を有する化合物
WO2018090869A1 (zh) 酰胺衍生物及其在药物中的应用
CN101778825A (zh) 适用作詹纳斯激酶抑制剂的n-杂环类化合物
JP6811233B2 (ja) Ｔｎｆアルファの修飾因子として有用な環状化合物
CN107735088B (zh) 组蛋白脱乙酰酶抑制剂及其组合物和使用方法
KR20250002323A (ko) 항바이러스성 헤테로사이클릭 화합물
JP2004514671A (ja) イミダゾールおよびベンゾイミダゾールカスパーゼのインヒビターならびにそれらの使用
CS262692B2 (en) Process for preparing new derivatives of 1h,3h-pyrrolo-/1,2-c/thiazole
JP2007527904A (ja) グリコーゲンホスホリラーゼ阻害剤としてのピロロピリジン−２−カルボン酸ヒドラジド化合物
CN113754635A (zh) 稠环类化合物及其制备方法和用途
KR20120113886A (ko) 잔틴 옥시다아제 저해제로서 효과적인 신규 화합물 및 그를 함유한 약제학적 조성물
AU2013336628A1 (en) 1 H-indole-3-carboxamide derivatives and use thereof as P2Y12 antagonists
JP2013506691A (ja) ホスファチジルイノシトール３−キナーゼのピラゾール阻害薬
HK1121750A (en) Caspase inhibitor prodrugs
CN117480164B (zh) 凝血因子XIa抑制剂及其制备方法和应用
MX2008001360A (en) Caspase inhibitor prodrugs
WO1999032459A1 (en) Chymase inhibitors
JPH11512409A (ja) 抗腫瘍剤・２−［２−［２−（ヒドロキシエチル）アミノ］エチル］−５−［［２−メチルアミノ）−エチル］アミノ］インダゾロ［４，３−ｇｈ］イソキノリン−６（２Ｈ）−オン
JP2024520752A (ja) 炎症状態の治療における置換５－（４－メチル－６－フェニル－４Ｈ－ベンゾ［ｆ］イミダゾ［１，５－ａ］［１，４］ジアゼピン－３－イル）－１，２，４－オキサジアゾールの使用

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1121750

Country of ref document: HK

C12 Rejection of a patent application after its publication
RJ01 Rejection of invention patent application after publication

Open date: 20080917

REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1121750

Country of ref document: HK